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Background: HIV-infected women, particularly those with advanced disease, may have higher rates of pregnancy
loss (miscarriage and stillbirth) and neonatal mortality than uninfected women. Here we examine risk factors for
these adverse pregnancy outcomes in a cohort of HIV-infected women in Zambia considering the impact of
infant HIV status.
Methods: A total of 1229 HIV-infected pregnant women were enrolled (2001–2004) in Lusaka, Zambia and followed
to pregnancy outcome. Live-born infants were tested for HIV by PCR at birth, 1 week and 5 weeks. Obstetric and
neonatal data were collected after delivery and the rates of neonatal (<28 days) and early mortality (<70 days) were
described using Kaplan-Meier methods.
Results: The ratio of miscarriage and stillbirth per 100 live-births were 3.1 and 2.6, respectively. Higher maternal
plasma viral load (adjusted odds ratio [AOR] for each log10 increase in HIV RNA copies/ml = 1.90; 95% confidence
interval [CI] 1.10–3.27) and being symptomatic were associated with an increased risk of stillbirth (AOR= 3.19; 95%
CI 1.46–6.97), and decreasing maternal CD4 count by 100 cells/mm3 with an increased risk of miscarriage (OR = 1.25;
95% CI 1.02–1.54). The neonatal mortality rate was 4.3 per 100 increasing to 6.3 by 70 days. Intrauterine HIV
infection was not associated with neonatal morality but became associated with mortality through 70 days
(adjusted hazard ratio = 2.76; 95% CI 1.25–6.08). Low birth weight and cessation of breastfeeding were significant
risk factors for both neonatal and early mortality independent of infant HIV infection.
Conclusions: More advanced maternal HIV disease was associated with adverse pregnancy outcomes. Excess
neonatal mortality in HIV-infected women was not primarily explained by infant HIV infection but was strongly
associated with low birth weight and prematurity. Intrauterine HIV infection contributed to mortality as early as
70 days of infant age. Interventions to improve pregnancy outcomes for HIV-infected women are needed to
complement necessary therapeutic and prophylactic antiretroviral interventions.
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Vertical transmissionBackground
In 2009, an estimated 1.4 million pregnant women were
living with HIV in low- and middle-income countries.
About 91% of those women in need of antiretroviral
drugs for preventing mother-to-child transmission were
in sub-Saharan Africa and 54% of women are estimated* Correspondence: lk24@columbia.edu
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reproduction in any medium, provided the orto have received the prophylactic drugs with recent
scale-up [1]. Besides the risk of HIV transmission,
maternal HIV infection is associated with increased risk
of adverse pregnancy outcomes. For example, a meta-
analysis of 31 studies showed almost a four-fold
increased risk of stillbirth among HIV-infected com-
pared to uninfected women [2], although some studies
have not observed this [3,4].
Several studies in sub-Saharan African countries have
also shown that infants born to HIV-infected women
have a significantly increased risk of low birth weight. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and infant mortality [7-9]. Generally, markers of more
advanced maternal disease, such as low CD4 cell counts
and high plasma viral loads, are associated with these
endpoints [9-11]. However, since these markers are also
strongly related to HIV transmission [12-14], it is not
clear whether infant HIV infection is a cause or a conse-
quence of these adverse events. One study that separated
HIV infections by their timing found that preterm birth
was associated with intrapartum but not with intrauter-
ine infection, suggesting prematurity as a risk factor
for intrapartum infection rather than a cause of preterm
delivery [15]. In some studies, intrauterine-infected chil-
dren had smaller weight-for-gestation than expected,
suggesting some growth consequences of early intrauter-
ine HIV infection [16,17].
HIV-infected infants have a substantially higher risk of
infant mortality compared to uninfected but exposed
infants [18,19]. In addition, infants infected intrauterine
or intrapartum have a worse prognosis than those
infected through breastfeeding [19-21]. But it is unclear
whether perinatally-acquired HIV infection will influ-
ence infant survival within the first months after birth.
Since LBW and preterm birth are the major risk factors
for neonatal and early infant mortality in all populations
regardless of HIV status, separating out independent
effects of these inter-related perinatal variables is com-
plex and requires large sample sizes [22,23]. One large
study in Tanzania found that among infants born to
HIV-infected mothers, LBW, not infant HIV infection,
was the strongest risk factor for neonatal mortality [21].
Here we investigate risk factors for miscarriage, still-
birth, neonatal mortality and early mortality among a
cohort of pregnant HIV-infected women followed as
part of a study in Lusaka, Zambia. We aim to identify
independent contributions of advanced maternal disease
and infant HIV status to adverse pregnancy and neo-
natal outcomes and focus on whether the timing of
infant HIV infection influences the risk of these
adverse outcomes.Methods
Study design
We report a secondary analysis of data collected as part
of the Zambia Exclusive Breastfeeding Study (ZEBS), a
randomized clinical trial to examine whether exclusive
breastfeeding to 4 months, followed by abrupt weaning,
could reduce postnatal HIV transmission and child
mortality. The study protocol and primary results have
been reported elsewhere [24-26]. Briefly, a total of 1435
HIV-positive pregnant women were recruited at two
antenatal care clinics in Lusaka between May 2001 and
September 2004 if they intended to breastfeed, acceptedto take single-dose nevirapine to prevent perinatal HIV
transmission and consented to be assigned to either of
the study and control groups. Antiretroviral therapy
(ART) only became available in the public sector as the
study was nearing completion. Written informed con-
sent was obtained from all study participants. The study
was approved by human subjects committees at all col-
laborating institutions.Study procedures
Socioeconomic and clinical data were collected at enroll-
ment. Maternal blood samples were drawn at enrollment
to test for CD4 cell counts (FACSCount; BD Immunocy-
tometry Systems), hemoglobin level (Hemocue system),
and plasma viral load (Roche Amplicor 1.5; Roche). All
women with positive results of routine syphilis screening
test (RPR) were treated with penicillin. Two subsequent
antenatal visits were scheduled before delivery. Data on
the circumstances of miscarriages and stillbirths were
collected from medical records if available or from inter-
view with the mothers. Gestational week at delivery was
calculated from the estimated gestational week at enroll-
ment, which was based on clinical examination (fundal
height) and self-report of last menstrual period (LMP).
In cases of discrepant gestational age estimates, the LMP
date was used. Heel stick blood samples of infants were
obtained at clinic visits scheduled at birth, 1 week and
5 weeks. DNA was extracted from each infant’s blood
sample and tested for HIV by real-time polymerase
chain reaction (PCR). All positive test results were con-
firmed by testing at least two samples. To rule out false
negative test results due to an inadequate sample, ampli-
fication of the beta-globin gene was performed to ensure
adequate cell numbers. Home visits were scheduled at
4 days after birth and 2, 3 and 7 weeks post-partum.
Study participants who did not return for the scheduled
antenatal or clinic visits were tracked and followed by
home-visit teams.Study variables
The primary outcomes of interest were miscarriage, still-
birth, neonatal mortality (infant’s death <28 days) and
early mortality (infant’s death <70 days). Miscarriage was
defined as spontaneous abortion of pregnancy occurring
before 24 gestational weeks, and stillbirth as fetal death
occurring at 24 gestational weeks or later. Low birth
weight (LBW) was defined as birth weight <2500 g, and
preterm birth as having <34 weeks of gestation. This
cut-off was selected since systematic under-estimation
of gestational age by 2–3 weeks was indicated by the
birth weight distribution. 30 infants did not have birth
weight data mainly due to delivery at home. Their birth
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at 1 week.
Maternal body mass index (BMI) at 1 month postpar-
tum was used as a predictor since women were enrolled
at different gestational weeks and often quite late in
pregnancy. 123 women who missed the one month visit
were included into models as a separate group. Breast-
feeding was defined as having stopped only if cessation
occurred before the illness preceding infant’s death or
loss to follow up. Stopping breastfeeding was considered
as a fixed-covariate and a time-dependent variable. After
November 2003, cotrimoxazole prophylaxis was intro-
duced for women with CD4 cell counts <200 cells/mm3
and the effects of cotrimoxazole were reported elsewhere
[27]. If women experienced weight loss, >30 days of diar-
rhea, fever or cough in the six months prior to enroll-
ment, or had history of thrush or tuberculosis, women
were considered as being symptomatic according to
World Health Organization criteria [28]. Further, each
symptom was individually examined.
The timing of HIV transmission was stratified into
three groups: 1) intrauterine transmission (IU) 2) in-
trapartum/early post-partum transmission (IP/ePP) and
3) no infection within 42 days after birth (NI). IU trans-
mission was presumed if PCR results were positive
within 3 days of birth. IP/ePP transmission was pre-
sumed if the PCR results were positive between 4 and 42
days after birth. If PCR results were negative at least for
42 days after birth, then the infants were presumed not
to be infected within 42 days (NI). Mortality among the
three groups with different timing of HIV transmission
was compared. The cut-off point of early mortality was
chosen at 70 days to measure the effect of IU and IP
infection over the 6 weeks period after the neonatal
period. Those with no PCR results were considered to
be of unknown HIV status.
Statistical analysis
Mantel-Haenszel relative risk (RR) of each factor on
each outcome was examined and reported with 95%
Confidence Intervals (CIs). For adjusted analysis, multi-
variable logistic regression was fitted. Variables with ’p-
value < .10 in univariable analysis were included and
were retained if significant (p-value <0.05) and their
odds ratios (ORs) were reported with 95% CIs. Kaplan-
Meier methods were used to calculate mortality rates for
IU, IP/ePP and NI infants and Cox Proportional Hazards
models to examine risk factors of neonatal mortality and
early mortality [29]. Unadjusted and adjusted hazard
ratios (HRs) were reported with 95% CIs. Continuous
and categorical variables were compared across groups
by two sided-Wilcoxon tests or t-tests and χ2 statistics,
respectively. All statistical analyses were performed by
SAS (version 9.2).Sensitivity analysis
Sensitivity analysis was performed to examine whether
infants with unknown HIV status biased the results.
First, we assumed that all infants with unknown status
are IU, IP or NI. Next we estimated the probability of IU
or IP transmission in the infants of unknown HIV status
among those who died or who were lost to follow up
separately based on a logistic regression model predict-
ing transmission from maternal CD4 cell counts and
plasma viral load. Finally, we calculated the expected
neonatal and early mortality rates that would have
occurred had these transmission rates occurred in each
group of IU, IP and NI infants.
Results
Cohort description
Of 1435 HIV-positive women in the study, 11 women
were not pregnant, 191 withdrew or were lost to follow
up and four women died before delivery. Of 1229
women, 3.4% were enrolled during the first trimester
and 62.7% during the second (median 26 weeks; IQR
20–31). There were 36 miscarriages and 30 stillbirths.
Thus, 1163 women gave birth to 1185 live-born infants
(26 non-singleton births including 21 pairs of twins both
born alive). For 53 women, live-births were known to
have occurred but no delivery or follow-up data were
available. Compared to all 1163 live-born infants, the
ratio of miscarriage and stillbirth per 100 live-births
were 3.1 (95% CI 2.2–4.3) and 2.6 (95% CI 1.8–3.7),
respectively. Among 1132 live-born infants with delivery
records from 1110 mothers, 14.3% had LBW, and 16.3%
were preterm. The probabilities of neonatal (<28 days)
and early (<70 days) mortality were 0.043 (n = 47, 95% CI
0.032–0.057) and 0.063 (n = 67, 95% CI 0.050–0.079),
respectively (Table 1). No woman with miscarriage or
stillbirth had started ART and only 6 women started ART
during pregnancy and 3 within 70 days post-partum.
Risk factors for miscarriage and stillbirth
Risk factors for miscarriage or stillbirth were examined
(Table 2). CD4 cell counts <350 cells/mm3 and history
of miscarriage were associated with an increased risk of
miscarriage. For stillbirth, plasma viral load ≥50,000/ml
and symptomatic HIV disease were significant risk fac-
tors as well as no previous pregnancies. In multivariable
analysis, only CD4 cell counts <350 cells/mm3 was
significantly associated with miscarriage. The odds ratio
for decreasing CD4 cell counts by 100 cells/mm3 was
1.25 (95% CI 1.02–1.54, p = 0.03). For stillbirth, plasma
viral load (adjusted OR [AOR] for each log10 increase in
HIV RNA copies/ml = 1.90; 95% CI 1.10–3.27), being
symptomatic (AOR=3.19; 95% CI 1.46–6.97) and no
previous pregnancy (AOR= 2.71; 95% CI 1.16–6.31)
remained as significant risk factors.
Table 1 Frequencies of adverse pregnancy outcomes
among 1229 HIV-infected pregnant women recruited in
Lusaka, Zambia




# of live-born infants
with birth records








<1500 g 15 1.3
1500–1999 g 33 2.9
2000–2499 g 113 10.1
≥2500 g 963 85.7
Mean± SD, g 2947.7 ± 531.7
Gestationc
<32 weeks 94 8.4
32–33 weeks 88 7.9
34–36 weeks 260 23.3
≥37 weeks 672 60.3
Mean± SD, weeks 37.6 ± 4.05
a Calculated using Kaplan-Meier life table methods.
b 8 infants are missing data on birth weight and weight at 1 week visit.
c 18 infants are missing data on gestational weeks estimated at enrollment.
Data suggested a systematic underestimation of gestation by 2–3 weeks.
Thus we estimate that only 16.3% of births were preterm by conventional
definitions of <37 weeks.
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Risk factors for LBW and preterm birth are shown in
Table 3. Higher plasma viral load, BMI <18.5 kg/m2 and
swollen glands in more than one place were associated
with both LBW and premature birth. In addition,
women with CD4 cell counts <350 cells/mm3 had an
increased risk of having LBW infants (RR= 1.57; 95% CI
1.16–2.12) compared to women with higher CD4
cell counts. Infants born to mothers with hemoglobin
<10 g/dl, clinical symptoms or history of tuberculosis
were more likely to be LBW. Less formal education
was associated with preterm birth and women aged
>30 years had a lower risk of preterm birth than women
aged 20–30 years.
In multivariable analysis, maternal plasma viral load
(AOR for each log10 increase = 1.30; 95% CI 1.03–1.66),
BMI <18.5 kg/m2 (AOR= 2.35; 95% CI 1.49–3.70),
hemoglobin <10g/dl (AOR= 1.50; 95% CI 1.04–2.16), a
history of swollen glands in more than one place (AOR=
1.64; 95% CI 1.02–2.63) or tuberculosis (AOR= 1.85;
95% CI 1.11–3.06) were each independently associated
with a higher risk of LBW. For preterm birth, BMI <18.5
kg/m2 was the strongest risk factor (AOR= 1.96; 95% CI1.27–3.04). History of swollen glands (AOR= 1.77; 95%
CI 1.14–2.73) and less formal education (AOR= 1.42;
95% CI 1.00–2.02) were independently associated with
preterm birth. Maternal age >30 years was still asso-
ciated with reduced risk of preterm birth (AOR= 0.62;
95% CI 0.38–1.00).Risk factors for neonatal and early mortality
Risk factors for neonatal and early mortality are shown
in Table 4. Preterm birth, LBW, APGAR scores and
cesarean delivery were strongly associated with an
increased risk of both neonatal and early mortality in
univariable analysis. History of tuberculosis and >30 days
of diarrhea were significant risk factors for both neonatal
and early mortality. Relative risks of these factors
were higher for neonatal mortality than for early mortal-
ity. Maternal health factors, namely CD4 cell counts
<350 cells/mm3, hemoglobin <10 g/dl, higher plasma
viral load, and BMI <18.5 kg/m2 were significantly asso-
ciated with an increased risk of early mortality, but not
with neonatal mortality.
Maternal death <70 days was associated with an
increased risk of both neonatal and early mortality but
many of these deaths occurred after infant death.
Restricting only to maternal deaths occurring before
infant death (18/1132; 1%), the association with early
mortality was attenuated. Stopping breastfeeding <70 days
was a significant risk factor for neonatal and early mortal-
ity. When fitted as a time-dependent variable, the asso-
ciation was further strengthened for both neonatal
mortality (HR= 15.02; 95% CI 5.20–43.43) and early mor-
tality (HR=15.37; 95% CI 7.39–31.97). Infants born to
mothers aged <20 years had a two-fold increased risk
of neonatal and early mortality and having more than one
child aged 5–16 years living in the household was asso-
ciated with a lower risk of early mortality.
In multivariable analysis, LBW, stopping breastfeeding
and young maternal age were significantly associated
with both neonatal and early mortality. Preterm birth
was only associated with neonatal mortality and low
maternal CD4 cell counts (<350 cells/mm3) only with
early mortality (Table 5, Model 1).Effects of infant HIV status
Among the 1132 infants, 50 infants had no HIV test
results. Of 1082 infants with a known HIV status,
64 infants (5.9%) were IU infected. Another 64 infants
(5.9%) were IP/ePP infected including 10 infants with
indeterminate HIV status at birth but tested HIV-
positive by 42 days. 863 infants were followed up and
not infected at least for 42 days. 69 infants were lost to
follow up but confirmed HIV-negative prior to 42 days
and another 22 infants were HIV-negative at birth or
Table 2 Risk factors for miscarriage and stillbirth among a cohort of 1229 HIV-infected womena
Ratio of miscarriages/









<350 24/652 (3.7) 2.20 (1.03–4.69) 19/647 (2.9) 1.44 (0.69–3.00)
≥350 9/538 (1.7) 11/540 (2.0)
Hemoglobin, g/dl
<10 12/352 (3.4) 1.34 (0.67–2.70) 7/347 (2.0) 0.73 (0.31–1.68)
≥10 21/826 (2.5) 23/828 (2.8)
Plasma viral load, copies/ml
≥50,000 19/540 (3.5) 1.62 (0.82–3.20) 19/540 (3.5) 2.05 (0.99–4.28)
<50,000 14/645 (2.2) 11/642 (1.7)
Clinical stage
Symptomatic 13/459 (2.8) 0.91 (0.47–1.78) 20/466 (4.3) 3.12 (1.47–6.61)
Asymptomatic 23/740 (3.1) 10/727 (1.4)
Socioeconomic and Clinical Factors
Age, year
<20 3/117 (2.6) 0.89 (0.27–2.90) 5/119 (4.2) 1.73 (0.66–4.49)
20-30 25/867 (2.9) 1.0 21/863 (2.4) 1.0
>30 8/215 (3.7) 1.29 (0.59–2.82) 4/211 (1.9) 0.78 (0.27–2.25)
Education
Some (0-8th grade) 26/755 (3.4) 1.53 (0.74–3.14) 22/751 (2.9) 1.62 (0.73–3.60)
HS grade (≥ 9th grade) 10/444 (2.3) 8/442 (1.8)
Electricity
No 22/718 (3.1) 1.05 (0.54–2.04) 20/716 (2.8) 1.33 (0.63–2.82)
Yes 14/481 (2.9) 10/477 (2.1)
Previous pregnancy
No 7/169 (4.1) 1.47 (0.66–3.30) 8/170 (4.7) 2.19 (0.99–4.83)
Yes 29/1030 (2.8) 22/1023 (2.2)
Previous miscarriages
Yes 7/111 (6.3) 2.37 (1.06–5.28) 5/109 (4.6) 1.99 (0.78–5.09)
No 29/1059 (2.7) 25/1084 (2.3)
Previous stillbirths
Yes 2/70 (2.9) 0.95 (0.23–3.87) 1/69 (1.5) 0.56 (0.08–4.06)
No 34/1129 (3.0) 29/1124 (2.6)
Rapid plasma reagin test
Positive 5/193 (2.6) 0.89 (0.35–2.29) 8/196 (4.1) 1.72 (0.78–3.81)
Negative 27/932 (2.9) 22/927 (2.4)
a All analyses are unadjusted.
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NI infants, giving a total of 954 NI infants (88.2%).
Neonatal mortality rates were 5.0 per 100 live-born
infants (95% CI 1.7–14.8) in IU infants, 1.6 (95% CI ’0.2–
10.6) in IP/ePP infants and 2.2 (95% CI 1.3–3.3) in NI
infants. By 70 days after birth, early mortality increased
to 13.7 per 100 (95% CI 7.1–25.5) in IU infants, 4.8 (95%
CI 1.6–14.1) in IP/ePP infants and 3.5 (95% CI 2.5–5.0)
in NI infants. Infants with IU infection had a non-
significant elevation in mortality by 28 days compared toNI infants (HR= 2.29; 95% CI 0.68–7.70). The risk asso-
ciated with IU infection increased when mortality
through 70 days was considered (HR= 3.93; 95% CI
1.81–8.53). Model 2 in Table 5 shows the associations be-
tween IU and IP/ePP transmission and neonatal and
early mortality in multivariable model. IU infection
remained significantly associated with early mortality
(AHR= 2.76; 95% CI 1.25–6.08) after adjustment for
LBW, preterm birth, stopping breastfeeding, and having
more than a child aged 5–16 years. IP/ePP infection was
Table 3 Risk factors for low birth weight (<2500g) and preterm birth among 1132 live-born infantsa








Male 79/587 (13.5) 0.88 (0.66–1.17) 97/583 (16.6) 1.03 (0.79–1.35)
Female 82/535 (15.3) 85/528 (16.1)
Maternal Health Factors
CD4 cells/mm3
<350 105/611 (17.2) 1.57 (1.16–2.12) 108/608 (17.8) 1.24 (0.94–1.63)
≥350 56/510 (11.0) 72/503 (14.3)
Hemoglobin, g/dl
<10 66/330 (20.0) 1.67 (1.25–2.23) 54/325 (16.6) 1.04 (0.78–1.40)
≥10 93/778 (12.0) 123/773 (15.9)
Plasma viral load, copies/ml
≥50,000 96/505 (19.0) 1.82 (1.36–2.45) 94/500 (18.8) 1.32 (1.01–1.72)
<50,000 64/614 (10.4) 87/609 (14.3)
Clinical stage
Symptomatic 73/431 (16.9) 1.33 (1.00–1.78) 68/427 (15.9) 0.96 (0.73–1.26)
Asymptomatic 88/693 (12.7) 114/687 (16.6)
History of tuberculosis
Yes 28/106 (26.4) 2.02 (1.42–2.88) 23/105 (21.9) 1.39 (0.94–2.05)
No 133/1018 (13.1) 159/1009 (15.8)
History of having swollen glands
Yes 29/138 (21.0) 1.57 (1.09–2.25) 34/138 (24.6) 1.62 (1.17–2.25)
No 132/984 (13.4) 148/975 (15.2)
BMI, kg/m2
<18.5 37/150 (24.7) 2.41 (1.71–3.39) 34/146 (23.3) 1.76 (1.25–2.47)
≥18.5 88/858 (10.3) 112/845 (13.3)
Socioeconomic and Clinical Factors
Age, year
<20 13/101 (12.9) 0.92 (0.54–1.57) 23/101 (22.8) 1.35 (0.92–2.00)
20–30 115/824 (14.0) 1.0 137/814 (16.8) 1.0
>30 33/199 (16.6) 1.19 (0.83–1.69) 22/199 (11.1) 0.66 (0.43–1.00)
Education
Some (0–8th grade level) 101/702 (14.4) 1.01 (0.75–1.36) 127/692 (18.4) 1.41 (1.05–1.89)
HS grade (≥9th grade level) 60/422 (14.2) 55/422 (13.0)
Electricity
No 102/671 (15.2) 1.17 (0.87–1.57) 119/668 (17.8) 1.26 (0.95–1.67)
Yes 59/453 (13.0) 63/446 (14.1)
Food run out at least 1 day in last month
Yes 32/244 (13.1) 0.89 (0.62–1.28) 46/245 (18.8) 1.20 (0.89–1.62)
No 129/879 (14.7) 136/868 (15.7)
a All analyses are unadjusted.
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not be directly examined in relation to neonatal mortality
since survival to a subsequent test was a component of
the definition of intrapartum infection. Major causes ofneonatal and early mortality were similar among the
three groups; pneumonia, acute diarrhea and septicemia.
When we examined the mortality between 28 and
70 days, the risk of the mortality among IU infants was
Table 4 Risk factors for neonatal mortality (<28 days) and early mortality (<70 days) among 1132 live-born infantsa
No. Neonatal mortality Early mortality
Mortality rate (n) Hazard ratio
(95% CI)




Male 592 0.042 (24) 1.00 (0.56–1.79) 0.067 (37) 1.18 (0.73–1.92)
Female 537 0.042 (22) 0.056 (29)
Gestation
Preterm 182 0.111 (19) 3.87 (2.15–6.95) 0.137(23) 3.03 (1.83–5.03)
Term 932 0.030 (27) 0.049 (43)
Birth weight, g
<2500 161 0.169 (26) 8.85 (4.89–15.99) 0.239 (36) 8.69 (5.30–14.24)
≥2500 963 0.020 (19) 0.031 (28)
APGAR score at 5 min
<7 17 0.647 (11) 42.78 (20.89–87.59) 0.718 (12) 34.17 (17.78–65.66)
≥7 995 0.027 (26) 0.045 (42)
APGAR score at 1 min
<7 30 0.580 (17) 43.32 (22.78–82.39) 0.627 (18) 31.06 (17.55–55.00)
≥7 989 0.023 (22) 0.041 (38)
Mode of delivery
C–section 35 0.205 (7) 6.12 (2.74–13.66) 0.239 (8) 5.00 (2.39–10.46)
Vaginal 1096 0.038 (40) 0.057 (59)
Maternal Health Factors
CD4 cells/mm3
<350 616 0.052 (31) 1.62 (0.89–2.96) 0.084 (49) 2.28 (1.33–3.92)
≥350 513 0.032 (16) 0.037 (18)
Hemoglobin, g/dl
<10 334 0.062 (20) 1.76 (0.99–3.14) 0.089 (28) 1.71 (1.05–2.78)
≥10 782 0.036 (27) 0.053 (39)
Plasma viral load, copies/ml
≥50,000 510 0.055 (27) 1.66 (0.93–2.95) 0.085 (41) 1.95 (1.19–3.18)
<50,000 617 0.034 (20) 0.045 (26)
Clinical stage
Symptomatic 434 0.047 (20) 1.16 (0.65–2.07) 0.070 (29) 1.20 (0.74–1.95)
Asymptomatic 698 0.040 (27) 0.058 (38)
>30 days of diarrhea in the 6 months prior to enrollment
Yes 8 0.286 (2) 7.18 (1.74–29.60) 0.286 (2) 5.21 (1.28–21.28)
No 1124 0.041 (45) 0.061 (65)
History of tuberculosis
Yes 107 0.113 (12) 3.32 (1.72–6.39) 0.133 (14) 2.55 (1.41–4.59)
No 1025 0.035 (35) 0.055 (53)
BMI, kg/m2
<18.5 151 0.027 (4) 2.84 (0.85–9.42) 0.061 (9) 2.86 (1.29–6.37)
≥18.5 858 0.009 (8) 0.022 (18)
Maternal death before infant’s death
Yes 18 0.056 (1) 1.28 (0.18–9.25) 0.278 (5) 4.85 (1.96–12.07)
No 1114 0.043 (46) 0.059 (62)
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Table 4 Risk factors for neonatal mortality (<28 days) and early mortality (<70 days) among 1132 live-born infantsa
(Continued)
Maternal death <70 days
Yes 18 0.282 (5) 7.95 (3.14–20.09) 0.521 (9) 11.47 (5.68–23.18)
No 1114 0.039 (42) 0.055 (58)
Stopped breastfeeding <70 days
Yes 36 0.112 (4) 2.75 (0.99–7.66) 0.260 (9) 4.75 (2.35–9.58)
No 1096 0.041 (43) 0.056 (58)
Socioeconomic and Clinical Factors
Age, year
<20 103 0.080 (8) 2.29 (1.05–4.99) 0.104 (10) 2.02 (1.02–4.02)
20–30 828 0.038 (30) 1.0 0.056 (44) 1.0
>30 201 0.046 (9) 1.24 (0.59–2.60) 0.067 (13) 1.21 (0.65–2.24)
Education
Some (0–8th grade level) 708 0.040 (27) 0.81 (0.46–1.45) 0.061 (40) 0.90 (0.55–1.47)
HS grade (≥9th grade level) 424 0.049 (20) 0.066 (27)
Electricity
No 676 0.043 (28) 1.00 (0.56–1.79) 0.068 (43) 1.22 (0.74–2.00)
Yes 456 0.043 (19) 0.055 (24)
Food run out at least 1 day in last month
Yes 247 0.033 (8) 0.72 (0.34–1.54) 0.060 (14) 0.93 (0.51–1.67)
No 884 0.046 (39) 0.064 (53)
# of children (<5 aged)
2+ 163 0.032 (5) 0.71 (0.28–1.79) 0.046 (7) 0.69 (0.31–1.50)
0 –1 969 0.045 (42) 0.066 (60)
# of children (5–16 aged)
2+ 360 0.026 (9) 0.49 (0.24–1.02) 0.037 (13) 0.49 (0.27–0.90)
0 –1 772 0.051 (38) 0.075 (54)
a All analyses are unadjusted.
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http://www.biomedcentral.com/1471-2431/12/138further elevated compared to NI infants (HR= 6.82; 95%
CI 2.40–19.35) and still significant after adjustment for
LBW and cessation of breastfeeding (AHR= 6.36; 95%
CI 2.22–18.27). Non-significant increase in mortality
was observed among IP/ePP infants (HR= 2.34; 95% CI
0.52–10.43).
To consider whether risk factors for neonatal and early
mortality were modified by infant HIV status, we strati-
fied the analysis by infant HIV status. In multivariable
model restricting to 128 infected infants, only LBW was
associated with neonatal mortality (HR= 16.63; 95% ’CI
1.73–160.16) and LBW (AHR= 16.13; 95% CI ’4.23–
61.48) and stopping breastfeeding (AHR= 8.15; 95% CI
1.62–40.92) with early mortality. Among 954 uninfected
infants, LBW (AHR=6.99; 95% CI 2.61–18.71) and
preterm birth (AHR=2.64; 95% CI 1.00–6.99) were
significantly associated with neonatal mortality. LBW
(AHR=6.47; 95% CI 3.13–13.34) and stopping breastfeed-
ing (AHR=9.52; 95% CI 3.65–24.85) were significantly
associated with early mortality as seen in whole population.Sensitivity analysis
The 50 infants with unknown HIV status had lower birth
weights and higher mortality rates than IU, IP and NI
infants. 23 infants (46%) died by 28 days and 24 infants
(48%) by 70 days. To determine the extent of bias, we
performed a sensitivity analysis including these infants
under different assumptions (Table 6).
The predicted probability of HIV transmission was
6.8% for IU and 6.9% for IP in the 24 infants who died
before 70 days and 4.4% for IU and 4.0% for IP in the 26
infants lost to follow up. Assuming these transmission
rates among the infants with unknown HIV status, we
calculated neonatal mortality rates of 7.3% in IU, 3.9% in
IP and 4.1% in NI groups. Early mortality rates were
15.6% in IU, 7.1% in IP and 5.5% in NI groups among
the 1132 infants. After this imputation, the adjusted
HRs of neonatal mortality and early mortality among
IU transmitted infants were 1.66 (95% CI 0.65–4.29)
and 2.09 (95% CI 1.05–4.17) compared to NI infants,
respectively (Model 4). This is similar to the results
Table 5 Multivariate analysis of risk factors for neonatal and early mortalitya
Neonatal mortality
Adjusted HR (95% CI)
Early mortality
Adjusted HR (95% CI)
Model 1
Low birth weight 6.10 (3.17–11.72) 7.52 (4.52–12.52)
Preterm birth 2.07 (1.08–3.94) n/a
Stopping breastfeeding 8.61 (2.46–30.09) 8.36 (3.91–17.89)
CD4 count <350/mm3 n/a 1.82 (1.03–3.24)
History of tuberculosis 2.36 (1.14–4.92) n/a
Maternal aged <20 years vs. 20–30 years 3.05 (1.3–6.81) 2.58 (1.24–5.38)
Having 2+ children age 5–16 years n/a 0.44 (0.24–0.82)
Model 2
HIV status
IU transmission 2.00 (0.58–6.89) 2.76 (1.25–6.08)
IP transmission 0.77 (0.10–5.80) 1.87 (0.56–6.16)
Low birth weight 6.69 (2.68–16.71) 8.11 (4.33–15.21)
Preterm birth 2.75 (1.13–6.69) n/a
Stopping breastfeedingb 5.50 (1.20–25.17) 9.84 (4.36–22.20)
Having 2+ children aged 5–16 years n/a 0.46 (0.22–0.96)
a Adjusted hazard ratios in models including all covariates as shown.
b Stopping breastfeeding was fitted as a time-dependent covariate.
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that the original approach was reasonable.
Discussion
This study documents that women with advanced
HIV disease are not only more likely to transmit HIV
but also have an increased risk of miscarriage and still-
birth and infants born to these mothers have an
increased risk of neonatal and early mortality. High rates
of neonatal and early mortality are primarily attributable
to low birth weight and preterm birth, both also
increased among women with advanced disease. It
is only after the neonatal period that the infant’s HIV
status begins to make a significant contribution to
excess mortality.
In this study, the risks of miscarriage and stillbirth
were 31 and 26 per 1000 live-born births, respectively.
From another cohort study in Lusaka, Zambia, the esti-
mated rate of stillbirth was 21 per 1000 live-born births
where 75.2% of the participating women were HIV-
uninfected [30]. We found that among HIV-infected
women, miscarriage was associated with CD4 cell counts
<350 cells/mm3. This result is similar to other studies
[31,32]. In a South African cohort study, women with
CD4 cell counts <250 cells/mm3 had a two-fold
increased risk of the adverse outcome (antenatal heath,
miscarriage or stillbirth) compared to those with CD4
cell counts >500 cells/mm3 [31]. Another study in India
reported that symptomatic women had a significantly
increased rate of miscarriage, compared to asymptomatic
women [32].In our study, high plasma viral load was significantly
associated with stillbirth among HIV-infected women.
Many studies have reported increased risk of stillbirth in
HIV-infected women compared to HIV-negative women
[2], but only two studies have examined risk factors
associated with stillbirth among HIV-infected pregnant
women [3,33]. A study in Tanzania found that elevated
CD3 count, but not other markers such as CD4 or CD8
counts, was associated with stillbirth [33]. In the cohort
conducted in four cities in sub-Saharan Africa, the risk
of stillbirth was correlated with decreasing CD4 count
[3] but not with plasma viral load categorized into
≥100,000 copies/ml or less. In our analysis, the mean
baseline plasma viral load of mothers who delivered still-
births was significantly higher (median value 76,560 vs.
39,783 copies/ml, p = 0.01) thus fitting it as a continuous
variable (log scale) seemed to be more accurate. Further-
more, symptomatic women had a more than a three-fold
increased risk of stillbirth compared to asymptomatic
women, suggesting that maternal disease progression
may play an important role in perinatal outcomes.
Some previous studies have tried to document HIV
status of pregnancy losses [34-36]. One study which did
so by in situ hybridization showed that 60% of the spon-
taneous fetal losses (6/10) were associated with HIV
transmission to the fetus [35]. It is possible that
advanced maternal disease might have increased preg-
nancy losses via intrauterine transmission [37,38] but we
could not directly examine such mechanism. Since ART
only became available towards the end of the study,
52 out of 66 women (79%) who had miscarriages or
Table 6 Sensitivity analyses for the 50 infants with unknown HIV status














IU 64 0.050 (3) 1.09 (0.34–3.50) 0.97 (0.30–3.18) 0.137 (8) 2.26 (1.08–4.73) 1.65 (0.77–3.50)
IP/ePP 64 0.016 (1) 0.35 (0.05–2.51) 0.39 (0.05–2.85) 0.048 (3) 0.78 (0.25–2.50) 1.11 (0.35–3.58)
NI at least for 42 days 1004 0.044 (43) 1.0 0.059 (56) 1.0
Model 2b
IU 114 0.268 (26) 14.82 (8.25–26.60) 12.03 (6.45–22.42) 0.347 (32) 12.65 (7.73–20.72) 8.15 (4.83–13.74)
IP/ePP 64 0.016 (1) 0.73 (0.10–5.40) 0.73 (0.10–5.47) 0.048 (3) 1.34 (0.41–4.39) 1.70 (0.52–5.58)
NI at least for 42 days 954 0.022 (20) 1.0 0.035 (32) 1.0
Model 3c
IU 64 0.050 (3) 2.28 (0.68–7.68) 1.88 (0.55–6.43) 0.137 (8) 3.89 (1.79–8.44) 2.70 (1.23–5.91)
IP/ePP 114 0.238 (24) 13.15 (7.25–23.84) 11.65 (6.23–21.79) 0.275 (27) 9.92 (5.93–16.58) 9.61 (5.58–16.54)
NI at least for 42 days 954 0.022 (20) 1.0 0.035 (32) 1.0
Model 4d
IU 67 0.080 (5) 1.94 (0.77–4.93) 1.66 (0.65–4.29) 0.164 (10) 2.98 (1.52–5.87) 2.09 (1.05–4.17)
IP/ePP 67 0.045 (3) 1.13 (0.35–3.65) 0.82 (0.20–3.41) 0.076 (5) 1.39 (0.56–3.48) 1.55 (0.56–4.32)
NI at least for 42 days 998 0.040 (39) 1.0 0.055 (52) 1.0
a Assume all of the 50 infants as NI at least for 42 days.
b Assume all of the 50 infants infected by IU transmission.
c Assume all of the 50 infants infected by IP/ePP transmission.
d HIV status of the 50 infants was imputed based on the predicted probability of HIV transmission.
e Adjusted for stopping breastfeeding, LBW, and preterm birth.
f Adjusted for stopping breastfeeding, LBW, and 2+ children (5–16 aged).
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WHO guidelines but did not. Although certain ART
regimens may increase the risk of adverse pregnancy
outcomes [39,40], it also reduces the risk of perinatal
transmission and improves maternal health [41]. Timely
ART for HIV-infected pregnant women may result in a
net improvement in these perinatal outcomes.
Our data indicate that HIV infection acquired during
pregnancy begins to contribute to excess mortality as
early as 70 days but mostly only after the neonatal
period, independent of LBW and early cessation of
breastfeeding. After the neonatal period, IU-infected
infants had more than a six-fold increased risk of mor-
tality compared to NI infants through 70 days. Prior
studies have not as precisely considered the timing of
early mortality of infected infants [19,20] nor separated
IU transmission from IP/ePP transmission [21]. Some
studies have found IU-infected infants to have onset of
symptoms in first few months of life and faster disease
progression than those infected at delivery or later
[15,42,43]. Despite recent scale-up, only 15% of HIV-
exposed infants had access to early infant diagnosis and
one-third of infants diagnosed of HIV did not receive
appropriate antiretroviral treatment in 2011 [44]. Our
results re-emphasize the crucial role of early infant diag-
nosis in order to initiate therapy for infected infants
given their rapid progression [45,46].LBW was previously associated with infant death be-
tween 8 weeks and 6 months of life [9], post-neonatal
death (29–365 days) and infant mortality [21] among
HIV-infected children as well as among HIV-exposed
uninfected [22]. Among perinatally-infected infants,
the effect of LBW on infant survival dominates the neo-
natal period but persists thereafter even once HIV-
related disease contributes to infant mortality. In our
study, high maternal viral load and low hemoglobin
were the most significant predictors of LBW and pre-
term birth as observed in other studies [4,16,47].
Advanced maternal disease seems to indirectly affect
early infant survival via the risk of LBW and
premature birth. Thus to complement antiretroviral
interventions, other interventions such as providing
cotrimoxazole [27] or multivitamin supplements during
pregnancy [48] may need to be considered to improve
overall birth outcomes.
Early breastfeeding cessation was a significant risk
factor for both neonatal and early mortality. Breastfeed-
ing has a significant role in infant survival for all infants
including those born to HIV-infected women [20,25,26].
Maternal death was also related to infant mortality and
is closely related to cessation of breastfeeding. However,
we found breastfeeding to be a strong protector of infant
survival independent of confounding effects of maternal
health and survival.
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vival. Infants with more than one sibling aged 5–16 years
had decreased rates of early mortality. This may reflect
families with greater birth spacing or substantial care
provided by an older sibling. Teenage pregnancy was
associated with an increased risk of neonatal and early
mortality. In the general population, some studies have
reported adverse associations between teenage pregnancy
and perinatal mortality, largely attributable to preterm
birth [49-51], while others have not [52]. In our study,
maternal age <20 years was associated with neonatal
mortality independent of preterm birth.
The study has several limitations. First, most of study
participants were enrolled into the study during second
or third trimester thus miscarriages and stillbirths occur-
ring in earlier gestational ages are excluded resulting in
underestimated rates of these outcomes. Our study thus
has limited capacity to comment on the predictors of
early pregnancy loss. However, most early pregnancy loss
is due to chromosomal abnormalities and is unlikely to
be influenced by maternal HIV status [53]. Second, dis-
tinguishing between miscarriage and stillbirth is difficult
particularly with inaccuracies in estimates of gestational
age. Nevertheless, similar factors were associated with
both of these adverse outcomes hence the consequence
of misclassification seems to be limited. Third, HIV sta-
tus could not be determined for some infants. However,
we examined the extent of bias in sensitivity analyses
which suggested that these exclusions did not appre-
ciably affect the results. Finally, the cut-off of 70 days
might have been too early to see any adverse effects of
IP/ePP infection but this analysis aimed to examine how
rapidly intrauterine and perinatally-acquired HIV infec-
tion affect infant survival.
Conclusion
Women with more advanced HIV disease had a higher
risk of pregnancy loss and perinatal mortality. Advanced
maternal HIV disease affected infant health and survival
directly via the risk of HIV transmission and indirectly
via LBW and prematurity. The effect of intrauterine
infection in the infant was apparent by 70 days but
excess neonatal mortality was primarily attributed to
LBW and preterm birth independent of infant HIV sta-
tus. Interventions to improve maternal health as well as
pregnancy outcomes for HIV-infected women may be
necessary to complement the currently recommended
prophylactic and therapeutic antiretroviral regimens.
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